Leveraging psychedelic therapies for binge eating disorder

Tryp Therapeutics examines the use of psychedelic-assisted psychotherapy for binge eating disorder. Their lead program, TRP-8803, uses an intravenous formulation of psilocin, the active metabolite of psilocybin, to achieve precise and reproducible blood levels, overcoming the variability of oral psilocybin administration. The text suggests this approach could improve clinical outcomes by ensuring consistent dosing, but it does not present any experimental results or data from human studies.

Study at a glance

Abstract

Leveraging psychedelic therapies for binge eating disorder Here Tryp Therapeutics examine the viability of using psychedelic therapies for Binge Eating Disorder and the potential results that using psychedelic-assisted psychotherapy could have on different eating disorders. Tryp Therapeutics is a clinical-stage biotechnology company dedicated to the development of exclusive and innovative formulations for administering psilocin in conjunction with psychotherapy, aiming to address unmet medical needs in various diseases. Our primary focus is on our lead program, TRP-8803, which represents a proprietary formulation of intravenous (IV) infused psilocin, the active metabolite of psilocybin. This formulation overcomes several limitations associated with oral psilocybin administration. By directly administering psilocin via the intravenous route, we achieve the most precise form of dosing, ensuring the reproducibility of blood levels necessary for clinical efficacy while preserving safety. In contrast, oral administration of psilocybin relies on enzymatic conversion of psilocybin to psilocin, resulting in substantial variability in drug blood levels among patients, potentially confounding the planned outcome of clinical studies.